Holdings in global healthcare ETFs

Otsuka Holdings Co Ltd, a major player in the global healthcare sector, appears as a key holding in the VanEck Global Healthcare Leaders ETF (ASX: HLTH), representing 2.05% of the fund's net assets as of the latest snapshot. The ETF provides diversified exposure to large international healthcare companies, with Otsuka listed alongside peers like Orion Oyj and Hoya Corp. This positioning highlights Otsuka's prominence in global healthcare portfolios accessible to US investors through international ETFs, according to VanEck as of May 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Otsuka Holdings Co Ltd: core business model

Otsuka Holdings Co Ltd operates as a holding company overseeing subsidiaries focused on pharmaceuticals, nutraceuticals, and consumer healthcare products. The group emphasizes research and development in areas such as neuroscience, oncology, and nephrology. Its portfolio includes branded drugs marketed globally, with a strong emphasis on innovative therapies. US investors may note Otsuka's exposure through partnerships and product approvals in the American market, enhancing its relevance amid rising demand for specialized treatments.

The company's structure supports diversified revenue streams, from prescription drugs to over-the-counter products. This model allows Otsuka to navigate regulatory landscapes across regions, including the US where certain subsidiaries contribute to clinical trials and distribution.

Main revenue and product drivers for Otsuka Holdings Co Ltd

Key products drive Otsuka's revenue, particularly in psychiatry and cardiovascular health. Abilify, a blockbuster antipsychotic, has been a historical driver, though patent expirations shifted focus to new launches. Recent efforts target nephrology with drugs like Samsca and oncology therapies. For US investors, Otsuka's pipeline offers exposure to high-growth areas in biotech, with ongoing R&D spend supporting future revenue.

Nutraceutical and imaging divisions provide stability, with sales in Asia and expanding in Western markets. The company's global footprint, including US operations, ties its performance to international healthcare trends relevant to American portfolios.

Industry trends and competitive position

The global healthcare sector faces innovation pressures, with biotech advancements and aging populations boosting demand. Otsuka competes with firms like Eli Lilly and Takeda in neuroscience, leveraging niche expertise. Its ETF inclusion signals strong fundamentals, appealing to US investors seeking diversified international healthcare plays beyond domestic giants like Amgen or Stryker, also held in the same fund.

Why Otsuka Holdings Co Ltd matters for US investors

Listed on the Tokyo Stock Exchange, Otsuka provides US investors with access to Japan's robust pharma sector via ADRs or ETFs like VanEck HLTH. Amid US healthcare spending growth, Otsuka's US market presence through subsidiaries offers indirect exposure to domestic trends without full currency risk.

Conclusion

Otsuka Holdings Co Ltd maintains a solid position in global healthcare ETFs, reflecting investor confidence in its diversified portfolio and R&D focus. While ETF holdings underscore stability, ongoing product developments and market expansions shape its trajectory. US investors tracking international healthcare may monitor these dynamics alongside broader sector shifts.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.